Regeneron Pharmaceuticals, Inc. — Q1 2015 Form 10-Q Summary
Business context and reporting period
Regeneron is an integrated biopharmaceutical company developing, manufacturing, and commercializing medicines for serious medical conditions. The filing covers the three months ended March 31, 2015, with unaudited financial statements compared with the three months ended March 31, 2014.
The business remained substantially dependent on EYLEA, which generated 62% of total revenue in the quarter. Regeneron also marketed ARCALYST and maintained a pipeline focused on ophthalmology, hypercholesterolemia, oncology, rheumatoid arthritis, asthma, atopic dermatitis, and other areas.
Financial performance and key metrics
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Total revenue | $869.6 million | $625.7 million | Up 39.0% |
| Net product sales | $544.6 million | $362.4 million | Up 50.3% |
| Operating expenses | $586.1 million | $434.2 million | Up 35.0% |
| Income from operations | $283.6 million | $191.6 million | Up 48.0% |
| Operating margin | 32.6% | 30.6% | Improved |
| Net income | $76.0 million | $68.3 million | Up 11.3% |
| Diluted earnings per share | $0.66 | $0.61 | Up 8.2% |
| Net margin | 8.7% | 10.9% | Declined |
| Net cash from operating activities | $(87.5) million | $53.5 million | Declined |
| Capital expenditures | $114.2 million | $64.8 million | Up 76.1% |
- U.S. EYLEA sales were $541.1 million, compared with $359.0 million in the prior-year quarter, driven primarily by higher volume. ARCALYST sales were $3.5 million, compared with $3.4 million.
- Sanofi collaboration revenue increased to $173.4 million from $130.5 million. The quarter included $14.9 million of previously deferred ZALTRAP revenue and $19.8 million of technology licensing and other revenue associated primarily with the amended ZALTRAP agreement.
- Bayer HealthCare collaboration revenue was $123.8 million, compared with $125.3 million. The quarter included a $15.0 million EYLEA sales milestone, versus $30.0 million of milestones in Q1 2014.
- Research and development expense increased to $343.1 million from $287.4 million, principally due to higher headcount, clinical activity, and manufacturing of Praluent supplies. Selling, general, and administrative expense increased to $159.0 million from $103.2 million.
- Non-cash stock-based compensation expense increased to $103.8 million from $75.8 million.
- Income tax expense was $200.5 million, and the effective tax rate increased to 72.5% from 62.2%, reflecting foreign losses, the non-deductible Branded Prescription Drug Fee, and expiration of the federal research tax credit.
Cash, liquidity, debt, and balance-sheet items
- Cash and cash equivalents were $507.9 million at March 31, 2015, down from $648.7 million at December 31, 2014.
- Total marketable securities were approximately $717.6 million, including $89.6 million of equity securities. Cash, cash equivalents, and marketable securities totaled approximately $1.2255 billion at quarter-end.
- Operating cash flow was negative because accounts receivable from trade customers and collaborators increased by $321.1 million, primarily reflecting lengthened payment terms for certain U.S. EYLEA customers.
- The company entered into a $750.0 million senior unsecured five-year revolving credit facility in March 2015. No borrowings were outstanding, and the company was in compliance with its covenants at quarter-end.
- Convertible senior notes had an aggregate principal amount of $162.7 million at March 31, 2015 and mature on October 1, 2016 unless converted earlier. The company settled $16.7 million of principal during the quarter through cash and stock.
- Regeneron paid $124.0 million in February 2015 to reduce outstanding warrants by 416,480 warrants. Total financing cash flow remained positive at $76.2 million, partly due to stock-option exercises and related excess tax benefits.
- Facility lease obligations were $328.4 million at quarter-end. Total liabilities were $1.227 billion, and stockholders’ equity was $2.971 billion.
Material changes versus the prior comparable period
- Revenue growth was led by higher EYLEA sales and increased Sanofi collaboration revenue.
- Operating income increased faster than revenue, but net income grew more slowly because of the substantially higher effective tax rate and increased operating costs.
- Operating cash flow shifted from a $53.5 million inflow to an $87.5 million outflow, primarily due to receivables growth.
- Capital spending rose materially as Regeneron expanded manufacturing capacity and invested in new Tarrytown facilities and the Limerick, Ireland facility.
- Regeneron and Sanofi amended the ZALTRAP agreement. Sanofi became solely responsible for global development and commercialization for cancer indications, assumed related costs, and Regeneron’s contingent obligation to reimburse approximately $461 million of previously funded development costs was eliminated.
- The company revised prior-period financial information for an immaterial stock-option accounting error. The revisions were non-cash and did not affect previously reported total operating cash flow.
- Headcount increased to an average of 3,066 from 2,389, reflecting expansion of research, development, manufacturing, and commercialization activities.
Guidance, outlook, commentary, risks, and unusual items
- Management expected capital expenditures of approximately $535 million to $635 million during the remaining three quarters of 2015, primarily for manufacturing expansion, facility improvements, Tarrytown tenant improvements, and the acquisition of adjacent land.
- Management stated that existing capital resources, the revolving credit facility, anticipated EYLEA sales, and collaborator reimbursements were expected to fund operating needs for the foreseeable future.
- Management expected continued increases in research and development, manufacturing, commercialization preparation, and EYLEA-related expenditures. The filing did not provide full-year revenue or earnings guidance.
- Praluent received FDA priority review, with a target decision date of July 24, 2015; the EMA application was also under review. Praluent remained subject to regulatory, safety, competitive, and intellectual-property uncertainties.
- Several pipeline programs faced partial clinical holds, including REGN1500 and fasinumab. Fasinumab was also subject to an FDA partial clinical hold related to potential nerve-growth-factor class safety concerns.
- Amgen had initiated patent litigation seeking to restrict the manufacture and sale of Praluent. The company stated that the matter had not progressed sufficiently to estimate a possible loss.
- Regeneron continued patent litigation concerning its ’287 and ’018 patents. The filing reported that a federal court had held the ’018 patent invalid and found no infringement by Merus, while Regeneron was unable to appeal at that time.
- In April 2015, an additional $127.3 million principal amount of convertible notes was surrendered for conversion, with settlement anticipated in Q2 2015.
- In April 2015, the company acquired approximately 100 acres adjacent to its Tarrytown location for $73.0 million to support future research, development, and office expansion.
- Principal business risks include dependence on EYLEA, customer concentration, pricing and reimbursement pressure, competition from Lucentis and off-label Avastin, regulatory approval and safety risks, manufacturing capacity and compliance, intellectual-property litigation, reliance on Sanofi and Bayer, and potential volatility in cash flow and stock-based compensation.
Most important facts for investors to verify
- Whether EYLEA sales growth and market share can offset concentration, reimbursement, pricing, and competitive risks.
- The timing and outcome of the FDA and EMA reviews for Praluent, including the impact of the Amgen patent litigation.
- Collection timing for the substantially higher trade and collaborator receivables and the resulting effect on operating cash flow.
- Whether the planned $535 million to $635 million of remaining 2015 capital expenditures remain on schedule and within expected funding capacity.
- The impact of the 72.5% effective tax rate, available tax credit carry-forwards, and future cash tax payments.
- Future obligations and settlement activity related to convertible notes, warrants, facility leases, collaborator reimbursements, royalties, and milestone payments.
- Progress, regulatory status, safety signals, and potential commercialization costs for sarilumab, dupilumab, REGN1500, fasinumab, and other pipeline candidates.
- The ultimate outcomes and possible financial effects of the ’287/’018 patent proceedings and the Praluent patent litigation.